Nkarta to Participate in Upcoming Investor Conferences
28 févr. 2024 08h01 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its...
Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition
09 déc. 2023 20h31 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today...
Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights
09 nov. 2023 16h02 HE
|
Nkarta, Inc.
FDA clearance of IND for NKX019 in lupus nephritis expands pipeline into autoimmune diseaseNKX019, a first-in-class engineered NK cell therapy, has disease-modifying potential in autoimmune disease...
Nkarta to Participate at Upcoming Investor Conferences
07 nov. 2023 08h02 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its...
Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis
17 oct. 2023 07h01 HE
|
Nkarta, Inc.
New pipeline program builds on academic studies of durable, drug-free remissions in patients with autoimmune disease after CD19-targeted cell therapy NKX019, an allogeneic CAR NK cell...
Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures
16 oct. 2023 16h01 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that...
Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights
10 août 2023 07h01 HE
|
Nkarta, Inc.
NKX101 clinical update highlights encouraging antileukemic activity in patients with AML using fludarabine/cytarabine (Flu/Ara-C) lymphodepletion regimenNKX019 clinical data presented at EHA 2023 and...
Nkarta to Participate at Upcoming Investor Conference
03 août 2023 08h02 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its...
Nkarta Appoints Alyssa Levin Chief Financial and Business Officer
05 juil. 2023 16h02 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia
27 juin 2023 07h01 HE
|
Nkarta, Inc.
Encouraging antileukemic activity seen with NKX101 in patients with AML, including several with high-risk features, using a modified lymphodepletion incorporating Ara-C (cytarabine)In patients with...